Sernova Biotherapeutics Inc SVA.TO
TSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.15% | -15.99% | -17.66% | -18.78% | -15.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.03% | -50.42% | -54.07% | -54.10% | -56.60% |
| Operating Income | 48.03% | 50.42% | 54.07% | 54.10% | 56.60% |
| Income Before Tax | 42.83% | 45.08% | 56.33% | 52.68% | 53.89% |
| Income Tax Expenses | -343.03% | -314.37% | -622.92% | 21.57% | -- |
| Earnings from Continuing Operations | 43.98% | 45.68% | 56.59% | 52.66% | 53.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.98% | 45.68% | 56.59% | 52.66% | 53.71% |
| EBIT | 48.03% | 50.42% | 54.07% | 54.10% | 56.60% |
| EBITDA | 47.45% | 50.93% | 54.56% | 54.55% | 56.92% |
| EPS Basic | 47.79% | 48.90% | 59.24% | 56.06% | 56.83% |
| Normalized Basic EPS | 46.67% | 47.91% | 58.74% | 55.88% | 56.85% |
| EPS Diluted | 47.79% | 48.90% | 59.24% | 56.06% | 56.83% |
| Normalized Diluted EPS | 46.67% | 47.91% | 58.74% | 55.88% | 56.85% |
| Average Basic Shares Outstanding | 7.06% | 5.30% | 5.60% | 6.95% | 7.27% |
| Average Diluted Shares Outstanding | 7.06% | 5.30% | 5.60% | 6.95% | 7.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |